Headache
-
To assess the reasons for switching triptans within migraine patients presenting to a specialty clinic. ⋯ A variety of treatment attributes are important in determining the reasons involved in switching a triptan. To assess this attributes can provide additional information to supplement the traditional tests of efficacy provided by randomized clinical trials.
-
Clinical Trial Controlled Clinical Trial
Early treatment of migraine with rizatriptan: a placebo-controlled study.
To evaluate the efficacy of rizatriptan when administered early during a migraine attack. ⋯ Rizatriptan is significantly more likely than placebo to produce a pain-free response within 2 hours when the drug is administered early in the migraine attack, when pain is mild rather than moderate or severe.
-
A 36-year-old man without significant past medical history presented with recurrent explosive headache at the time of orgasm. Magnetic resonance angiography showed focal mid-basilar artery narrowing. Despite receiving no specific therapy, the patient's headaches and vascular narrowing had resolved completely on follow-up six months later. While a number of pharmacologic agents have been proposed to be of benefit in orgasmic headache, this case suggests that spontaneous resolution may also occur.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
To evaluate the efficacy and tolerability of montelukast 20 mg in the prophylactic treatment of migraine. ⋯ Montelukast 20 mg was well tolerated in migraine patients but was not an effective prophylactic for prevention of migraine.
-
Comparative Study
The medical costs of migraine and comorbid anxiety and depression.
To examine the direct medical costs associated with migraine, when diagnosed alone and in conjunction with anxiety and/or depression in adults and children. ⋯ This analysis quantifies the economic impact of a migraine diagnosis for both adults and children. The results of this analysis demonstrate that individuals identified as migraineurs have significantly higher medical costs than healthy comparators, with or without comorbid anxiety and/or depression. This study also suggests that clinicians should be aware that while proper treatment of migraine with effective acute and prophylactic therapy is important, attention must also be directed to comorbid conditions.